This hormone signals satiety to the brain, slows gastric emptying, and influences insulin secretion
Ricks told CNBC Wednesday that Lilly had held off on advertising Zepbound and launching the drug internationally in order to boost inventory in the U.S.: We havent been stimulating demand the way we had originally planned. Yet on the earnings call, Ricks maintained that underlying growth for the drugs was as strong as we would have hoped. Ricks asserted that Lilly management did not view the gap between the Q3 results and the projections of even higher growth as indicating a softening of demand for the GLP-1 drugs: Demand for Mounjaro and Zepbound has been strong and continues to grow as we expand both access and supply. Johnson denied that competition from compounders had a huge financial impact on Lillys business
WE CHECKED IN WITH BLUE CROSS BLUE SHIELD ABOUT INSURANCE COVERAGE: Blue Cross and Blue Shield of Alabama does cover GLP-1 drugs (glucagon-like-peptide 1 agonists) that are FDA approved for treating type 2 diabetes such as Ozempic, Trulicity, and others
Importantly, AOD-9604 did not produce any of the adverse effects associated with growth hormone therapy, including glucose intolerance, insulin resistance, edema, joint pain, or tissue growth abnormalities
And so the side roads that would take you somewhere are actually better because theyre not blocked